Dean of School of Pharmacetic Science，Director of Shandong Key Laboratory of Targeted Drug Delivery & High-End Formulations，Director of Shandong University Industry-University-Research Collaborative Innovation Center for Cell Therapy，Director of Shandong University Center for Biotherapy

Professor, School of Pharmacetic Science，

Shandong University, No.44 Wenhua West Road, Jinan, Shandong Province, P.R.China

Email: xinyijiang@email.sdu.edu.cn

Website: www.pharm.sdu.edu.cn/info/1340/20445.htm

Xinyi Jiang obtained his Ph.D. from Fudan University in 2012 and served as the postdoctoral researcher at Stanford University during 2013 to 2017. Dr. Jiang is now a full professor at Shandong University. Dr. Jiang has published over 50 original research papers in prestigious journals such as Nature Biotechnology, Nature Cancer，Nature Nanotechnology, Science Translational Medicine， PNAS, Science Advanced and etc. Dr. Jiang is an Editorial Board member of Scientific Reports, Asian Journal of Pharmaceutical Sciences, and etc. He is also a youth member of the Chinese Pharmaceutical Association Committee and a member of the China Particle Society-Bioparticle Professional Committee. In the last 5 years, he has presided many a project including the National Natural Science Foundation of China Research, Funds for Shandong Provincial Key Research and Development Program (Major Scientific and Technological Innovation Project), Fundamental Research Funds of Shandong Province and Fund of Stanford University, and participated in 2 research project of NIH RO1 Research Fund in the United States. As the Project leader, he completed one of the Alliance for Cancer Gene Therapy (ACGT) funds. Dr. Jiang’s research is now focusing on Nucleic acid drug delivery, nanomedicine and tissue regeneration.

Representative Publications

(1) Jing Zhang#, Chen Chen#, et al., Xinyi Jiang*. Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection. Nature Nanotechnology, 2021, 16, 538–548

(2) Xiaotian Zhao, et al., Xinyi Jiang*. A logic-gated trispecific engager enhances macrophage killing of cancer cells in solid tumors. Nature Biotechnology, 2026, DOI:10.1038/s41587-026-03057-9

(3) Yulin Zhang, et al., Xinyi Jiang*. Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice. Cell Host & Microbe, 2026, DOI:10.1016/j.chom.2025.12.014

(4) Weiqiang Jing#, Maosen Han#, et al., Xinyi Jiang*.  An in-situ engineered chimeric IL-2 receptor potentiates the tumoricidal activity of proinflammatory CAR macrophage in renal cell carcinoma，Nature Cancer, 2025，6, 838-853.

Zhenguo Wu, et al., Xinyi Jiang*. Engineered CAR-monocytes coordinate fibrosis clearance and cardiac regeneration following myocardial infarction. Cell Stem Cell, 2026, DOI:10.1016/j.stem.2026.04.003